William Blair Comments on ResMed’s Q3 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Equities research analysts at William Blair boosted their Q3 2025 earnings estimates for shares of ResMed in a research note issued on Friday, December 6th. William Blair analyst M. Andrew now forecasts that the medical equipment provider will post earnings per share of $2.37 for the quarter, up from their prior forecast of $2.33. The consensus estimate for ResMed’s current full-year earnings is $9.34 per share. William Blair also issued estimates for ResMed’s Q4 2025 earnings at $2.44 EPS and FY2025 earnings at $9.30 EPS.

Other research analysts have also recently issued reports about the stock. StockNews.com raised shares of ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Needham & Company LLC reiterated a “hold” rating on shares of ResMed in a research note on Friday, October 25th. Baird R W upgraded shares of ResMed to a “strong-buy” rating in a research report on Tuesday, September 24th. Bank of America boosted their target price on shares of ResMed from $240.00 to $270.00 and gave the company a “buy” rating in a research report on Thursday, September 26th. Finally, KeyCorp lifted their price target on shares of ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $225.70.

ResMed Trading Up 1.3 %

Shares of NYSE RMD opened at $244.63 on Monday. ResMed has a 1 year low of $162.18 and a 1 year high of $260.49. The stock has a market cap of $35.91 billion, a P/E ratio of 32.40, a price-to-earnings-growth ratio of 1.75 and a beta of 0.68. The firm has a 50-day moving average of $242.31 and a 200 day moving average of $226.81. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.92 and a quick ratio of 1.91.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, topping the consensus estimate of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The firm had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.19 billion. During the same period last year, the company posted $1.64 EPS. The company’s quarterly revenue was up 11.1% compared to the same quarter last year.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date is Thursday, November 7th. ResMed’s payout ratio is 28.08%.

Insider Activity at ResMed

In other news, Director Peter C. Farrell sold 2,000 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $245.65, for a total value of $491,300.00. Following the transaction, the director now directly owns 81,218 shares in the company, valued at approximately $19,951,201.70. This represents a 2.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Witte Jan De sold 796 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total transaction of $198,052.76. Following the completion of the sale, the director now directly owns 6,723 shares of the company’s stock, valued at approximately $1,672,749.63. This trade represents a 10.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 52,725 shares of company stock valued at $12,516,248 over the last 90 days. 0.71% of the stock is owned by corporate insiders.

Institutional Trading of ResMed

A number of hedge funds have recently added to or reduced their stakes in the business. True Wealth Design LLC lifted its position in shares of ResMed by 2,200.0% during the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 110 shares during the last quarter. OFI Invest Asset Management acquired a new position in ResMed in the 2nd quarter worth approximately $32,000. Ashton Thomas Securities LLC acquired a new position in ResMed in the 3rd quarter worth approximately $34,000. Financial Connections Group Inc. acquired a new stake in shares of ResMed during the 2nd quarter worth approximately $37,000. Finally, Blue Trust Inc. grew its stake in shares of ResMed by 182.7% during the 2nd quarter. Blue Trust Inc. now owns 212 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 137 shares during the period. 54.98% of the stock is owned by hedge funds and other institutional investors.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.